Note 2 Equity Method Investment

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE

2

– EQUITY METHOD INVESTMENT

The Company has an equity method investment in Helomics. The unaudited

six

-month condensed statement of operations is as follows:

Helomics Holdings Corporation
	For the Six Months Ended
	June 30, 2018
Revenue	$	118,697
Gross margin	$	(25,539	)
Net loss from continuing operations	$	(4,285,054	)
Net loss to investee	$	(3,324,546	) 1

1

The loss to investee was calculated at

80%

for the initial period of ownership,

January 11, 2018 –

February 27, 2018,

and then at

75%

for the remainder of the

six

-month period at the current equity investment percentage owned by the Company.

Helomics’

first

six

months included diagnostic revenue only. The contract research organization and D-CHIP Artificial Intelligence products are in the process of launching and have therefore

not

yet generated any revenues. Additionally, there was a

$1.2M

one

-time expense for the conversion of notes payable into new notes that carry interest and warrants.